[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].  Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications.
In the last 5 years, there have been several reports of severe, sometimes lethal, listeriosis infection in patients treated with alemtuzumab.
This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy.
In January 2018, a meeting of the expert Council was held, at which the clinical recommendations published in 2017 were revised and updated.
